Rebecca A Dumont Walter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5944434/publications.pdf

Version: 2024-02-01

31 papers 1,485 citations

430874 18 h-index 27 g-index

31 all docs

31 docs citations

times ranked

31

2720 citing authors

#	Article	IF	CITATIONS
1	Olfactory Neuroblastoma: Re-Evaluating the Paradigm of Intracranial Extension and Cyst Formation. Diagnostics, 2022, 12, 614.	2.6	1
2	Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis. The Cochrane Library, 2021, 2021, CD013700.	2.8	7
3	Radioisotope imaging for discriminating benign from malignant cytologically indeterminate thyroid nodules. Gland Surgery, 2019, 8, S118-S125.	1.1	14
4	Therapeutic Options for Neuroendocrine Tumors. JAMA Oncology, 2019, 5, 480.	7.1	67
5	Test–Retest Reliability of Graph Theoretic Metrics in Adolescent Brains. Brain Connectivity, 2019, 9, 144-154.	1.7	24
6	MEK Inhibition Induces Therapeutic Iodine Uptake in a Murine Model of Anaplastic Thyroid Cancer. Journal of Nuclear Medicine, 2019, 60, 917-923.	5.0	7
7	Clinical Utility of Diffusion-Weighted Imaging in Spinal Infections. Clinical Neuroradiology, 2019, 29, 515-522.	1.9	27
8	Imaging-Based Approach to Extradural Infections of the Spine. Seminars in Ultrasound, CT and MRI, 2018, 39, 570-586.	1.5	15
9	Reply: Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine Tumors: Methodologic Issues. Journal of Nuclear Medicine, 2017, 58, 1532.1-1532.	5.0	0
10	The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 468-475.	6.4	52
11	Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine Tumors. Journal of Nuclear Medicine, 2017, 58, 97-102.	5.0	7
12	Reply: Somatostatin Receptor–Targeted Radiopeptide Therapy in Patients with Progressive Unresectable Meningioma. Journal of Nuclear Medicine, 2016, 57, 1657.2-1658.	5.0	0
13	Somatostatin Receptor–Targeted Radiopeptide Therapy with ⁹⁰ Y-DOTATOC and ¹⁷⁷ Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial. Journal of Nuclear Medicine, 2015, 56, 171-176.	5.0	63
14	Towards tailored radiopeptide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1231-1237.	6.4	12
15	Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinoma. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 46-55.	1.0	15
16	Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist - from Mice to Men. Theranostics, 2014, 4, 412-419.	10.0	127
17	Targeted Radiotherapy of Prostate Cancer with a Gastrin-Releasing Peptide Receptor Antagonist Is Effective as Monotherapy and in Combination with Rapamycin. Journal of Nuclear Medicine, 2013, 54, 762-769.	5.0	68
18	Inflammatory neovascularization during graft-versus-host disease is regulated by $\hat{l}\pm\nu$ integrin and miR-100. Blood, 2013, 121, 3307-3318.	1.4	75

#	Article	lF	CITATIONS
19	CLIC4 is a tumor suppressor for cutaneous squamous cell cancer. Carcinogenesis, 2012, 33, 986-995.	2.8	42
20	Correlation of the Genotype of Paragangliomas and Pheochromocytomas with Their Metabolic Phenotype on 3,4-Dihydroxy-6- ¹⁸ F-Fluoro-l-Phenylalanin PET. Journal of Nuclear Medicine, 2012, 53, 1352-1358.	5.0	39
21	Radioactive Therapy and External Radiotherapy of Thyroid Cancer. , 2012, , 313-326.		O
22	Novel $\langle \sup 64 \langle \sup Cu \rangle$ and $\langle \sup 68 \langle \sup Ca \rangle$ Ga-Labeled RGD Conjugates Show Improved PET Imaging of $\hat{l}_{2} \langle \sup \hat{l}_{2} \langle \sup \hat{l}_{2} \langle \sup \hat{l}_{3} \rangle$ Integrin Expression and Facile Radiosynthesis. Journal of Nuclear Medicine, 2011, 52, 1276-1284.	5.0	141
23	¹⁸ F-FDOPA PET and PET/CT Accurately Localize Pheochromocytomas. Journal of Nuclear Medicine, 2009, 50, 513-519.	5.0	90
24	Derivation of a Compartmental Model for Quantifying 64Cu-DOTA-RGD Kinetics in Tumor-Bearing Mice. Journal of Nuclear Medicine, 2009, 50, 250-258.	5.0	33
25	Noninvasive Imaging of $\hat{l}\pm\hat{Vl^2}$ 3 Function as a Predictor of the Antimigratory and Antiproliferative Effects of Dasatinib. Cancer Research, 2009, 69, 3173-3179.	0.9	48
26	Development of a Real-time RT-PCR Assay for Detecting EGFRvIII in Glioblastoma Samples. Clinical Cancer Research, 2008, 14, 488-493.	7.0	91
27	CLIC4 mediates and is required for Ca2+-induced keratinocyte differentiation. Journal of Cell Science, 2007, 120, 2631-2640.	2.0	51
28	Monitoring Tumor Glucose Utilization by Positron Emission Tomography for the Prediction of Treatment Response to Epidermal Growth Factor Receptor Kinase Inhibitors. Clinical Cancer Research, 2006, 12, 5659-5667.	7.0	199
29	Antisense suppression of the chloride intracellular channel family induces apoptosis, enhances tumor necrosis factor {alpha}-induced apoptosis, and inhibits tumor growth. Cancer Research, 2005, 65, 562-71.	0.9	43
30	The Organellular Chloride Channel Protein CLIC4/mtCLIC Translocates to the Nucleus in Response to Cellular Stress and Accelerates Apoptosis. Journal of Biological Chemistry, 2004, 279, 4632-4641.	3.4	126
31	Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis. The Cochrane Library, 0, , .	2.8	1